You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (See section 4.4 Special warnings and precautions for use and section 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colourless system, about 6.1cm in diameter, square, with rounded corners, on an oversized transparent protective liner. The backing film is imprinted with code "CG HKH".
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (See section 4.4 Special warnings and precautions for use and sectoin 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colourless system, about 4.9 cm square, with rounded corners, on an oversized, transparent protective liner. The product identification code is heat-stamped on the backing film as CG GSG.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing( See section 4.4 Special warnings and precautions for use and section 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colorless system, about 7.0 cm square, with rounded corners, on an oversized, transparent protective liner.,The product identification code is heat-stamped on the backing film as CG GTG.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Estraderm MX 25 is not indicated for the prevention of post-menopausal bone mineral density loss. Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer
A translucent, colorless system, about 3.5 cm square, with rounded corners, on an oversized, transparent protective liner.,The product identification code is heat-stamped on the backing film as CG GRG.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (See section 4.4 Special warnings and precautions for use and section 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colourless system, about 6.1cm in diameter, square, with rounded corners, on an oversized transparent protective liner. The backing film is imprinted with code "CG HKH".
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (See section 4.4 Special warnings and precautions for use and section 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colourless system, about 6.1cm in diameter, square, with rounded corners, on an oversized transparent protective liner. The backing film is imprinted with code "CG HKH".
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (See section 4.4 Special warnings and precautions for use and sectoin 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colourless system, about 4.9 cm square, with rounded corners, on an oversized, transparent protective liner. The product identification code is heat-stamped on the backing film as CG GSG.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Estraderm MX 25 is not indicated for the prevention of post-menopausal bone mineral density loss. Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer
A translucent, colorless system, about 3.5 cm square, with rounded corners, on an oversized, transparent protective liner.,The product identification code is heat-stamped on the backing film as CG GRG.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Menopausal symptoms: Short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. In women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (Refer to section 5.1 Pharmacodynamic properties - Clinical Trials and section 4.2 Dose and method of administration). Prevention of post-menopausal bone mineral density loss: Estraderm MX 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estraderm MX should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing( See section 4.4 Special warnings and precautions for use and section 4.2 Dose and method of administration). Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.
A translucent, colorless system, about 7.0 cm square, with rounded corners, on an oversized, transparent protective liner.,The product identification code is heat-stamped on the backing film as CG GTG.
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
